



Final Announcement


Belgian Society on Thrombosis and Haemostasis



ANNUAL MEETING
26 - 27 November 2009

Château de Colonster
Liège
Belgium

Local organizer:
Muriel Sprynger
University Hospital Centre Sart Tilman
Cardiology and Angiology
Liège - Belgium



09h30 Registration

10h00 Welcome

S. Motte
President of the BSTH

New drugs, new concepts in arterial and venous thrombosis - Part 1



Boehringer
Ingelheim

Satellite Symposium

Chair P. Verhamme (KUL) and J-L. David (ULg)

10h05 Dabigatran: Development and validation of
a new oral anticoagulant

C. Hermans (Brussels)

10h30 Dabigatran for stroke prevention in atrial
fibrillation (AF): results of the RELY-study

H. Heidbüchel (Leuven)

11h20 Break

State of the Art Lecture

Chair A. Demulder (ULB) and H. Deckmyn (KUL Kortrijk)

11h45 The role of membrane remodelling, microparticles
and related inflammation in thrombosis

O. Morel (Strasbourg)

12h10 Lunch

New insights into Venous and Arterial Thrombosis



Bayer HealthCare
Bayer Schering Pharma

Satellite Symposium

Longer acting FVIII & Longer life expectancy: challenges and perspectives in Haemophilia

Chair	C. Hermans (UCL) and A. Gadisseur (UZA)	
13h45	New Factor VIII and VIIa Products in BSP for Advanced Haemophilia Treatment	G. Lemm (Berlin)
14h10	Management of problems in elderly haemophilia patients	G. Dolan (Nottingham)
14h35	Cardiovascular diseases in elderly haemophilia patients: Incidence and management	E. Mauser-Bunschoten (Utrecht)

15h00 Oral Communications

Chair K. Jochmans (VUB) and H. Deckmyn (KUL Kortrijk)

16h15 Break


State of the Art Lecture

New drugs, new concepts in arterial and venous thrombosis - Part 2

Chair	M. Hoylaerts (KUL) and P. Hainaut (UCL)	
16h45	When to stop anticoagulation for venous thromboembolic disease?	P. Prandoni (Padua)
17h30	Development of new antiplatelet agents	M. Cattaneo (Milan)

18h15 Reception





08h30 Registration

09h00 Welcome

Thrombosis and cancer



Satellite Symposium

Chair S. Motte (ULB) and P. Verhamme (KUL)

09h05	Nadroparine and angiogenesis in a cancer mouse model	W. Ceelen (Ghent)
09h30	Protech data (role of LMWH (nadroparine) for ambulatory cancer patients with chemotherapy	G. Agnelli (Perugia)
09h50	Need of prolonged prophylaxis for cancer patient undergoing surgery	A. Cohen (London)

10h20 Break

State of the Art Lecture

Chair	K. Devreese (UZG) and K. Jochmans (VUB)	
10h45	JAK2 and MPL mutations. What is their impact on diagnosis and prognosis of abdominal venous thrombosis?	D.C. Valla (Paris)

11h30 Oral communications

Chair K. Peerlinck (KUL) and Ph. Hainaut (UCL)

12h45 Lunch

13h30 Poster presentations

New insights into Venous and Arterial Thrombosis

13h30

BSTH General Assembly

Open to effective members of the BSTH only

Biotherapies for Life™ **CSL Behring** Satellite Symposium

Peri-operative management of von Willebrand disease

Chair

A. Gadisseur (UZA)

14h15

Diagnosis of von Willebrand disease subtypes:
implications for treatment

U. Budde (Hamburg)

14h40

How to manage patients with VWD during surgery:
the results of clinical trials

A.B. Federici (Milan)

15h05

Peri-operative management of VWD: practice-based

F. Leebeek (Rotterdam)

15h30

Break

State of the Art Lecture : New therapeutic issues

Chair

M. Sprynger (ULg) and J-C. Wautrecht (ULB)

16h00

Combined antiplatelet and anticoagulant therapy
therapy: clinical benefits and risks

J. Eikelboom (Hamilton)

16h45

Can statins prevent venous thromboembolism ?
How could we explain Jupiter's results ?

P.W. Kamphuisen (Amsterdam)

17h30

Paul Capel Prize 2009

17h35

Closure

S.Motte President of the BSTH



> REGISTRATION

The registration fee is € 75,- including:

1. Participation to BSTH scientific meetings and Satellite Symposia on Thursday 26 and Friday 27 November 2009
2. Membership fee for the year 2010
3. Breaks, lunches and reception.

Registration can be done online at www.bsth.be.

Registration on-site is € 85,-.

> CALL FOR ABSTRACTS

Presentation: page A4, to be sent before **15th October 2009** to:

Dr. Muriel Sprynger

Cardiology-Vascular Medicine

CHU Liege

Sart Tilman

4000 Liège, BELGIUM

Email: msprynger@chu.ulg.ac.be.

Presentations will be judged by the board of the BSTH and selected for oral or poster presentation.


ACCREDITATION HAS BEEN REQUESTED



> MEETING VENUE

The meeting will be organized at
Château de Colonster
Université de Liège - Sart Tilman
Allée des Erables, 25
B - 4000 Liège

For further details see www.colonster.ulg.ac.be



> ORGANIZATION

Dr. Muriel Sprynger
Cardiology-Vascular Medicine, CHU Liège - Sart Tilman
Tel +32 (0) 43667111
Email msprynger@chu.ulg.ac.be
Web www.bsth.be

Meeting secretariat:
Con-txt Event & Congress Organisation
Weesboom 13
8061 LR Hasselt NL
Tel + 31 (0)38 4605601
Fax + 31 (0)38 4650602
Email info@con-txt.nl
Web www.con-txt.nl

> ACCOMMODATION

A large number of rooms in different hotel categories have been reserved. If you wish to make hotel reservations benefitting from discounted room rates, please contact the meeting secretariat.



The BSTH symposium is supported by the pharmaceutical industry

Major sponsors are:



Bayer HealthCare
Bayer Schering Pharma



GlaxoSmithKline

Biotherapies for Life™

CSL Behring



Boehringer
Ingelheim

other sponsors are:

BAXTER WYETH

Astrazeneca CAF-DCF IL Kordia LEO Pharma Nodia
Novo Nordisk Octapharma Roche Sanofi-Aventis Siemens

Visa number: 09/V2/2032/001254

